3 days Ago By ABMN Staff
Bokf Na lowered its stake in shares of Agilent Technologies, Inc. ( NYSE:A – Free Report ) by 50.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The firm owned 5,862 shares of the medical research company’s stock after selling 5,863 shares during the quarter. Bokf Na’s holdings in Agilent Technologies were worth $760,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also bought and sold shares of the company.
Crewe Advisors LLC increased its holdings in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares during the period.
Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies in the 4th quarter valued at $26,000. Ridgewood Investments LLC acquired a new stake in shares of Agilent Technologies in the 2nd quarter valued at $29,000. Rise Advisors LLC boosted its stake in shares of Agilent Technologies by 527.
8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc.
acquired a new stake in shares of Agilent Technologies in the 1st quarter valued at $34,000. Institutional investors own 87.42% of the company’s stock.
Insider Buying and Selling In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.
00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink .
0.33% of the stock is owned by company insiders. Agilent Technologies Price Performance Agilent Technologies ( NYSE:A – Get Free Report ) last posted its earnings results on Wednesday, August 21st.
The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.
06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.
75%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.
56 billion. During the same period in the prior year, the business earned $1.43 EPS.
Agilent Technologies’s revenue for the quarter was down 5.6% compared to the same quarter last year. Analysts anticipate that Agilent Technologies, Inc.
will post 5.24 earnings per share for the current fiscal year. Analyst Ratings Changes Several equities research analysts have recently commented on A shares.
Evercore ISI boosted their target price on shares of Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a research note on Thursday, August 22nd.
TD Cowen boosted their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd.
Citigroup upped their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd.
Robert W. Baird dropped their price objective on Agilent Technologies from $147.00 to $136.
00 and set an “outperform” rating for the company in a report on Thursday, May 30th. Finally, Bank of America boosted their price objective on Agilent Technologies from $140.00 to $147.
00 and gave the stock a “neutral” rating in a report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $141.
60. Read Our Latest Analysis on Agilent Technologies Agilent Technologies Company Profile ( Free Report ) Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. Further Reading Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc.
( NYSE:A – Free Report ). Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter .
.
